Dezhou Second People's Hospital and Qilu Pharmaceutical Discuss New Plans for Drug Clinical Trial Collaboration

On October 15, Dezhou Second People's Hospital and Qilu Pharmaceutical Co., Ltd. held in-depth discussions on the 2026 drug clinical trial (GCP) cooperation plan. Gao Limin, Party Secretary of the hospital and Director of the Institution, Yang Zhihong, Deputy Party Secretary, President of the hospital, and Deputy Director of the Institution Office, along with the heads of relevant departments, attended the meeting.

Gao Limin, on behalf of the hospital, extended a warm welcome to the representatives of Qilu Pharmaceutical for their return visit. He reviewed the achievements made by both parties since the start of the cooperation. The hospital’s clinical trial projects have demonstrated a high level in quality control, process standardization, and team execution, laying a solid foundation for planning future collaborations.

At the symposium, the two parties conducted an in-depth discussion on core issues. The focus of the exchange was on how to further leverage the hospital's strong professional advantages in the field of oncology to precisely align with Qilu Pharmaceutical's innovative drug development pipeline. The meeting comprehensively and pragmatically planned the cooperation model for drug clinical trials in 2026, as well as key disease areas and other content.

At the end of the meeting, Gao Limin highly praised the consensus reached during this exchange and looked forward to future cooperation prospects. He emphasized: "Clinical drug trials are an important way to promote medical science and technology progress and benefit a large number of patients, as well as the core of high-quality hospital development."Driving Force"One. The hospital will always adhere to a scientific, rigorous, and standardized approach in conducting every research project. The hospital is highly confident in collaborating with top innovative pharmaceutical companies in China such as Qilu Pharmaceutical Co., Ltd. We look forward to both parties working hand in hand by 2026, combining our strengths to achieve more groundbreaking results in drug development for major diseases like cancer, and jointly contributing to the advancement of China's medical and health care industry."

The successful holding of this exchange conference has drawn a clear blueprint for the smooth development and deep expansion of the hospital's drug clinical trials in 2026, and will surely bring more opportunities for patients in Dezhou and surrounding areas to receive cutting-edge treatments. (Wang Xiaojun)